Egypt Pharmaceuticals & Healthcare Q4 2018
Egypt will remain an attractive yet challenging market for multinational pharmaceutical firms. The near-term pictureremains uncertain as the weak currency and regulations over drug pricing continue to create difficult market conditions. Thecountry's designation as a ‘Watch List' country in PhRMA's 2018 submission highlights discriminatory market access policies, andlow levels of intellectual property protection as ongoing concerns for multinational drugmakers. Egypt's long-term story is morepositive, and the country will benefit from a number of key pharmaceutical market drivers, supporting a greater multinationalpresence.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook